---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012740"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T07:56:39.901627+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Lipocine to Present at H.C. Wainwright Conference Sept 8-10, 2025

## Summary
- Company management will present and hold 1x1 meetings at H.C. Wainwright 27th Annual Global Investment Conference in New York.
- Conference runs September 8-10, 2025; presentation available from 7:00 a.m. EDT on Sept 5.
- Lipocine's pipeline includes LPCN 1154 (postpartum depression), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), and others.
- TLANDO (testosterone undecanoate) is FDA-approved for hypogonadism; company exploring partnerships for several candidates.

## SEC filing metadata
- accession: 0001493152-25-012740
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225012740/0001493152-25-012740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225012740/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012740
- JSON: https://secwatch.observer/filing/0001493152-25-012740.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.